Table 5.
Univariate analysis of potential prognostic factors associated with hepatitis in DLBCL patients with resolved hepatitis B
| Factor | Without hepatitis [cases (%)] | With hepatitis [cases (%)] | P value |
|---|---|---|---|
| Total | 43 | 12 | |
| HBeAb | 0.639 | ||
| – | 38 (88.4) | 10 (83.3) | |
| + | 5 (11.6) | 2 (16.7) | |
| Age (years) | 0.831 | ||
| ≤60 | 23 (53.5) | 6 (50.0) | |
| >60 | 20 (46.5) | 6 (50.0) | |
| Sex | 0.340 | ||
| Female | 21 (48.8) | 4 (33.3) | |
| Male | 22 (51.2) | 8(66.7) | |
| ECOG PS | 0.974 | ||
| 0–1 | 36 (83.7) | 10 (83.3) | |
| ≥2 | 7 (16.3) | 2 (16.7) | |
| B symptoms | 0.763 | ||
| − | 34 (79.1) | 9 (75.0) | |
| + | 9 (20.9) | 3 (25.0) | |
| Ann Arbor stage | 0.168 | ||
| I–II | 24 (55.8) | 4 (33.3) | |
| III-IV | 19 (44.2) | 8 (66.7) | |
| Liver involvement | 0.447 | ||
| − | 41 (95.3) | 12 (100) | |
| + | 2 (4.7) | 0 (0) | |
| Spleen involvement | 0.873 | ||
| − | 40 (93.0) | 11 (91.7) | |
| + | 3 (7.0) | 1 (8.3) | |
| Involved extranodal sites | 0.275 | ||
| <2 | 35 (81.4) | 8 (66.7) | |
| ≥2 | 8 (18.6) | 4 (33.3) | |
| Bone marrow involvement | 0.594 | ||
| − | 42 (97.7) | 12 (100.0) | |
| + | 1 (2.3) | 0 (0.0) | |
| IPI score | 0.288 | ||
| 0–1 | 18 (41.9) | 3 (25.0) | |
| 2–5 | 25 (58.1) | 9 (75.0) | |
| ALT | 0.037 | ||
| ≤40 U/L | 39 (90.7) | 8 (66.7) | |
| >40 U/L | 4 (9.3) | 4 (33.3) | |
| AST | 0.005 | ||
| ≤45 U/L | 41 (95.3) | 8 (66.7) | |
| >45 U/L | 2 (4.7) | 4 (33.3) | |
| TB | 0.918 | ||
| ≤20.5 μmol/L | 39 (90.7) | 11 (91.7) | |
| >20.5 μmol/L | 4 (9.3) | 1 (8.3) | |
| LDH | 0.894 | ||
| ≤245 U/mL | 26 (60.5) | 7 (58.3) | |
| >245 U/mL | 17 (39.5) | 5 (41.7) |
Abbreviations as in Table 1.